PROTEOMICS & GENOMICS
Addressing Unmet Diagnostic Needs
Redefining diagnostics requires innovation on several fronts: informatics & analysis, new technology, and collaboration across disciplines. This is our strategy:
1. Emphasize Analysis & Biomarker Selection
We focus our resources on selecting clinically relevant biomarkers – using high-quality in-licensed data sets – for capital efficiency and a swifter path to commercialization.
2. One Platform: Mass Spectrometry
We’ve selected one platform, MRM mass spectrometry (mass spec), that allows us to go from discovery to verification, validation and beyond, with “no loss in translation.” Loss is what happens when biomarker data discovered using one technology platform cannot be developed further on another platform.
3. Create Technology That Drives Innovation
We’re working with our partners to develop new technologies – including proprietary applications of MRM mass spec – that allow us to quickly and cost effectively create assays that can monitor hundreds of proteins simultaneously. Casting a wider net allows us to isolate the biomarkers with the greatest clinical relevancy.
4. Elevate Proteomics to the Scale of Genomics
To gain comprehensive, systems level knowledge, we conduct a whole proteome scan, evaluating every organ and disease specific protein for their diagnostic power. We focus on diseases that will benefit from a blood-based diagnostic – ones that are not well served by genetic or tissue-based diagnostics.
5. Build a New Diagnostics Ecosystem & Execute
We believe our strongest asset is our ability to bring together the right people – pioneering scientists & experienced executives, visionary investors & technology innovators, plus many more – to execute our mission of creating a new generation of diagnostics.